丽珠集团(000513.SZ)：莱康奇塔单抗注射液上市许可申请获受理

Core Viewpoint - LIZHU Group's subsidiary, Zhuhai Lizhu Antibody Biotechnology Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the domestic production registration application of "Lai Kangi Ta Monoclonal Antibody Injection" [1] Group 1 - The drug is a joint development with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. [1] - "Lai Kangi Ta Monoclonal Antibody Injection" is the first domestically developed and the second globally progressing innovative IL-17A/F dual-target inhibitor [1] - The drug targets psoriasis, a chronic inflammatory skin disease affecting approximately 100 million patients worldwide [1]